Nov 4, 2022Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces RelapseChildren with high-risk Hodgkin lymphoma were 10% less likely to relapse following treatment with brentuximab vedotin combination.Read more: https://www.roswellpark.org/newsroom/202211-pediatric-multicenter-study-shows-targeted-therapy-high-risk-hodgkin-lymphoma
Children with high-risk Hodgkin lymphoma were 10% less likely to relapse following treatment with brentuximab vedotin combination.Read more: https://www.roswellpark.org/newsroom/202211-pediatric-multicenter-study-shows-targeted-therapy-high-risk-hodgkin-lymphoma